Showing 119 of 119on this page. Filters & sort apply to loaded results; URL updates for sharing.119 of 119 on this page
CT1812 | 1802632-22-9
CT1812 (Sigma-2 receptor antagonist 1) | CAS 1802632-22-9 | AbMole ...
Structures of CT1812 (1), [¹⁸F]ISO-1 (2), and (3) | Download Scientific ...
Chemical structure of CT1812. | Download Scientific Diagram
Structures of UKH-1114 (1), Siramesine (2), [¹⁸F]ISO-1 (3), CT1812 (4 ...
Sigma-2 receptor modulator CT1812 alters key pathways and rescues ...
CT1812 concentrations in cerebrospinal fluid (CSF) increased in a ...
Is the σ2 Receptor Allosteric Antagonist CT1812 (Elayta®) also an ...
How CT1812 Could Enhance Synaptic Function in Alzheimer's Patients ...
A pilot study to evaluate the effect of CT1812 treatment on synaptic ...
(PDF) CT1812 biomarker signature from a meta‐analysis of CSF proteomic ...
A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer ...
Commercial Route Development of Sigma-2 Receptor Modulator, CT1812 ...
[PPT] - The Anti-A Oligomer Drug CT1812 for Alzheimers: Phase 1b/2a ...
Plasma concentrations of CT1812 following a single oral dose (SAD) or ...
A PILOT ELECTROENCEPHALOGRAPHY STUDY OF THE EFFECT OF CT1812 TREATMENT ...
A Pilot Electroencephalography Study of the Effect of CT1812 Treatment ...
Agonist-bound structure of the human P2Y12 receptor - PMC
The role of SAXS and molecular simulations in 3D structure elucidation ...
Conversations Episode 7: Effects of CT1812 on Measures of Synaptic ...
Estudio MAGNIFY de CT1812 oral para la atrofia geográfica secundaria a ...
SHINE trial: CT1812 slows cognitive decline in Alzheimer's
对一项 2 期临床试验进行中期探索性蛋白质组学生物标志物分析，以评估 CT1812 对阿尔茨海默病的影响,Neurobiology of ...
Discovery of Investigational Drug CT1812, an Antagonist of the Sigma-2 ...
The Allosteric Antagonist of the Sigma-2 Receptors—Elayta (CT1812) as a ...
CT1812, a Small Molecule Sigma-2 Receptor Antagonist for Alzheimer’s ...
Clinical Update on an Anti-Alzheimer Drug Candidate CT1812: A Sigma-2 ...
CT-1812 – Drug Approvals International
【Drug Hunter】2024 年 2 月关注分子 - 知乎
GRAPHIC
Structures of Siramesine (4), UKH-1114 (5), CB-184 (6) [¹⁸F]ISO-1 (7 ...
Our approach to neurodegenerative diseases
A Review of the Clinical Progress of CT1812, a Novel Sigma-2 Receptor ...
#ad #alzheimersawarenessmonth #alzheimers #dementia #aging #ct1812 ...
Cognition Therapeutics: Shines Less Bright After Phase 2 Results In ...
Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer’s ...
Preclinical and clinical biomarker studies of CT1812: A novel approach ...
A new drug has shown promise for Dementia with Lewy Bodies in the just ...
(PDF) Preclinical and clinical biomarker studies of CT1812: A novel ...
Cognition Therapeutics focused on modifying degenerative disorders ...
Cognition Therapeutics, Inc. on LinkedIn: #ct1812 #sigma2 #aβoligomers ...
Table 3 from The Allosteric Antagonist of the Sigma-2 Receptors—Elayta ...
Sigma-2 Receptors—From Basic Biology to Therapeutic Target: A Focus on ...
Figure 4 from Explorer Preclinical and clinical biomarker studies of ...
As Biopharma Giants Reshape the Field, Cognition Therapeutics Sees a ...
The Sigma Receptors in Alzheimer’s Disease: New Potential Targets for ...
CTAD-2023 – Cognition Therapeutics, Inc.
CT1812CSF Datasheet(PDF) - Central Technologies
(PDF) A phase 1 clinical trial of the sigma-2 receptor complex ...
SEQUEL (COG0202) – Cognition Therapeutics, Inc.
Identification of cerebrospinal fluid pharmacodynamic biomarkers and ...
Cognition Therapeutics Announces Positive Results in Phase 2 Study of ...
Cognition Therapeutics, Inc. on LinkedIn: #sequel #ct1812 # ...
(PDF) The Allosteric Antagonist of the Sigma-2 Receptors—Elayta (CT1812 ...
Our Trials and Target Product Profile
An Outline of the Latest Crystallographic Studies on Inhibitor-Enzyme ...
Rational Drug Design and Synthesis of Molecules Targeting the ...
Current Strategies to Guide the Antiplatelet Therapy in Acute Coronary ...
速递｜穿越血脑屏障，阿尔茨海默病创新口服疗法最新临床结果发布_腾讯新闻
#adpd2025 #ct1812 #alzheimer #dementia #dementiawithlewybodies ...
(PDF) Identification of cerebrospinal fluid pharmacodynamic biomarkers ...
Table 1 from A Pilot Electroencephalography Study of the Effect of ...
A hypothetical model of PGRMC1 involvement in AD. (A) This crude ...
Phase 2 study of zervimesine (CT1812) in participants with mild‐to ...
In This Issue | PNAS
Structural studies identify angiotensin II receptor blocker-like ...
Synthetic Strategies toward SGLT2 Inhibitors | Organic Process Research ...
Recent Advances in Covalent Drug Discovery
Julius Clinical on LinkedIn: #alzheimersresearch # ...
